A Platinum‐Aluminum Bimetallic Salen Complex for Pro‐senescence Cancer Therapy
ChemBioChem · 2024
DOI: 10.1002/cbic.202400105 ↗Kurz gefasst
Fachartikel in der Zeitschrift ChemBioChem, 2024. Verfasst von Juan Tang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Beijing National Laboratory for Molecular Sciences, State Key Laboratory of Rare Earth Materials Chemistry and Applications, College of Chemistry and…. Hauptthemen laut MEDLINE: Antineoplastic Agents, Ethylenediamines, Cellular Senescence, Platinum. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 95 Literaturangaben. Gefördert von: National Scientific Foundation of China.
Abstract (Originalsprache)
Cell senescence is defined as irreversible cell cycle arrest, which can be triggered by telomere shortening or by various types of genotoxic stress. Induction of senescence is emerging as a new strategy for the treatment of cancer, especially when sequentially combined with a second senolytic drug capable of killing the resulting senescent cells, however severely suffering from the undesired off‐target side effects from the senolytic drugs. Here, we prepare a bimetalic platinum‐aluminum salen complex (Alumiplatin) for cancer therapy‐a combination of pro‐senesence chemotherapy with in situ senotherapy to avoid the side effects. The aluminum salen moiety, as a G‐quadruplex stabilizer, enhances the salen's ability to induce cancer cell senescence and this phenotype is in turn sensitive to the cytotoxic activity of the monofunctional platinum moiety. It exhibits an excellent capability for inducing senescence, a potent cytotoxic activity against cancer cells both in vitro and in vivo , and an improved safety profile compared to cisplatin. Therefore, Alumiplatin may be a good candidate to be further developed into safe and effective anticancer agents. This novel combination of cell senescence inducers with genotoxic drugs revolutionizes the therapy options of designing multi‐targeting anticancer agents to improve the efficacy of anticancer therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Beijing National Laboratory for Molecular Sciences, State Key Laboratory of Rare Earth Materials Chemistry and Applications, College of Chemistry and Molecular Engineering, Peking University, Beijing, 100871, P. R. Chin…
- Key Laboratory of Medicinal Molecule Science and pharmaceutics Engineering, Ministry of Industry and Information Technology, Key Laboratory of Cluster Science of Ministry of Education, School of Chemistry and Chemical E…
- Department of Chemistry, Jinan University, Guangzhou, 510632, P. R. China.
- Beijing National Laboratory for Molecular Sciences, CAS Key Laboratory of Analytical Chemistry for Living Biosystems, National Centre for Mass Spectrometry in Beijing, CAS Research/Education Center for Excellence in Mol…
ORCID-Profile: Jun-Long Zhang
Förderung
- National Scientific Foundation of China
Zitieren
APA
Tang, J., Yang, Y., Yin, H. Y., Ma, B., Zhu, M., Yang, Z. S., Peng, X. X., Jia, F., Zhao, Y., Wang, F., Chen, T., & Zhang, J. L. (2024). A Platinum‐Aluminum Bimetallic Salen Complex for Pro‐senescence Cancer Therapy. ChemBioChem. https://doi.org/10.1002/cbic.202400105
Vancouver
Tang J, Yang Y, Yin HY, Ma B, Zhu M, Yang ZS, et al. A Platinum‐Aluminum Bimetallic Salen Complex for Pro‐senescence Cancer Therapy. ChemBioChem. 2024. doi:10.1002/cbic.202400105
BibTeX
@article{Tang2024,
author = {Tang, Juan and Yang, Yahui and Yin, Hao-Yan and Ma, Bin and Zhu, Mengliang and Yang, Zi-Shu and Peng, Xin-Xin and Jia, Feifei and Zhao, Yao and Wang, Fuyi and Chen, Tianfeng and Zhang, Jun-Long},
title = {A Platinum‐Aluminum Bimetallic Salen Complex for Pro‐senescence Cancer Therapy},
journal = {ChemBioChem},
year = {2024},
doi = {10.1002/cbic.202400105}
}
EUVIMED